Drug intelligence / Profile preview

Lysonac

Development stage: Unknown
Lead developer: El Dorado Bio Tech

Overview

**Lysonac** is an El Dorado Bio Tech orthopedic analgesic brand umbrella rather than a uniquely defined active pharmaceutical product. Public product listings identify distinct Lysonac-labelled formulations with different active-ingredient combinations, including Lysonac ASP containing aceclofenac + paracetamol + serratiopeptidase, Lysonac T containing thiocolchicoside + aceclofenac + paracetamol, and Lysonac Plus containing diclofenac potassium + paracetamol + serratiopeptidase. Consequently, no single modality, molecular mechanism, route, dosage form, or ingredient composition can be assigned to the unqualified name \"Lysonac\" without a formulation suffix. ([1mg.com](https://www.1mg.com/drugs/lysonac-asp-100mg-325mg-15mg-tablet-339865))

Brand names: Lysonac

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Lysonac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysonac.

Explore the full profile